Interim Report January – June 2019

April – June 2019

• Net sales increased by 18 percent to SEK 1,176.7 million (997.4). Organic growth in local currency was 15 percent.
• Gross profit increased by 29 percent to SEK 321.1 million (248.6). Organic growth in local currency was 26 percent.
• Adjusted EBITDA² increased by 17 percent to SEK 114.2 million (97.4).
• Adjusted EBIT³ amounted to SEK 104.1 million (91.2).
• Profit after tax for the quarter amounted to SEK 53.3 million (29.0).
• Diluted earnings per share were SEK 0.98 (0.54).

January – June 2019

• Net sales increased by 23 percent to SEK 2,278.4 million (1,856.0). Organic growth in local currency was 16 percent¹.
• Gross profit increased by 36 percent to SEK 610.6 million (448.6). Organic growth in local currency was 24 percent¹.
• Adjusted EBITDA² increased by 39 percent to SEK 226.4 million (162.3).
• Adjusted EBIT³ amounted to SEK 206.3 million (149.9).
• Profit after tax for the period amounted to SEK 111.1 million (38.3).
• Diluted earnings per share amounted to SEK 2.06 (0.71).

“Although one-way business texting is now moving from early adopters to early majority, most businesses have yet to capitalize on the tremendous opportunities that rich media messaging and interactive conversations now bring about.” – Oscar Werner, CEO

Significant events during the quarter

• A partnership between Sinch and WIT Software to accelerate the global use of next-generation messaging services through Rich Communication Services (RCS) was announced on 5 April. Sinch will be using WIT Software’s technology as part of its RCS-as-a-Service offering to mobile operators that require an efficient and scalable solution to offer RCS to their subscribers and enterprise customers.
• On 11 April, Sinch announced changes to the company’s management team aimed at closer collaboration between the teams that address operator customers and enterprise customers. The Sinch management team now consists of: Chief Executive Officer Oscar Werner, Chief Operating Officer Anders Olin, Chief Financial Officer Roshan Saldanha, Chief Human Resources Officer Eva Lessing, Chief Technology Officer Jonas Lindeborg, Chief Marketing Officer Jonathan Bean, Chief Strategy Officer and Head of Investor Relations Thomas Heath, Chief Evangelist and Co-Founder Robert Gerstmann, Head of Corporate Development and Co-Founder Björn Zethraeus and Head of Business Development and Co-Founder Johan Hedberg.
• The name change from CLX Communications AB (publ) to Sinch AB (publ) was registered at the Swedish Companies Registration Office on 20 June.

¹  Organic growth in local currency in comparable units. Unwire and Vehicle, two acquisitions that did not close until the end of March 2018, are included in the entire comparison period of January – June 2018 in order to calculate growth in comparable units.

²  EBITDA excluding items affecting comparability. See page 3 for a specification of items affecting comparability.
³  EBIT excluding items affecting comparability and amortization of acquisition-related assets. See Note 4 for a specification of depreciation and amortization.

Invitation to phone conference

Sinch will present the interim report in a phone conference on 19 July at 9:00 CET. To participate in the phone conference, please call any of the following numbers and state the code 7278264.

Sweden:                            +46 (0) 8 506 921 85
UK:                                     +44 (0) 203 009 5710
USA:                                   +1 917 720 0178

Register here to watch the presentation via Webcast: investors.sinch.com/webcast

For additional information, please contact:

Thomas Heath, Chief Strategy Officer and Head of Investor Relations
+46 72 245 50 55
thomas.heath@sinch.com

Roshan Saldanha, Chief Financial Officer                                                                                                                 
+46 73 660 24 19

About Sinch

Sinch brings businesses and people closer with tools enabling personal engagement. Its leading cloud communications platform lets businesses reach every mobile phone on the planet, in seconds or less, through mobile messaging, voice and video. Sinch is a trusted software provider to mobile operators, and its platform powers business-critical communications for many of the world’s largest companies. Sinch has been profitable and fast-growing since its foundation in 2008. It is headquartered in Stockholm, Sweden, and has local presence in more than 30 countries. Shares are traded at NASDAQ Stockholm: XSTO:SINCH. Visit us at sinch.com.

Note: Sinch AB (publ) is required to publish the information in this interim report pursuant to the EU market abuse regulation. The information was submitted for publication on 19 July 2019 at 07.30 CET.

This report is published in Swedish and English. In case of any differences between the English version and the Swedish original text, the Swedish version shall apply. This report has not been subject to review by the company’s independent auditor.

Attachment

• Sinch_2019Q2_ENG

NEW YORK, July 18, 2019 (GLOBE NEWSWIRE) — Afya Limited (“Afya”) today announced the pricing of its initial public offering of 13,744,210 Class A common shares at a public offering price of $19.00 per share. Afya is issuing and selling 11,827,256 shares of Class A common shares and certain selling shareholders are selling an additional 1,916,954 shares of Class A common shares. The shares are expected to begin trading on the Nasdaq Global Select Market on July 19, 2019, under the symbol “AFYA” and the offering is expected to close on July 23, 2019. In connection with the offering, Afya has granted the underwriters a 30-day option to purchase up to an additional 2,061,631 shares of Class A common shares at the initial public offering price less the underwriting discount.

BofA Securities, Inc., Goldman Sachs & Co. LLC, UBS Securities LLC and Itau BBA USA Securities, Inc. are acting as Global Coordinators in this initial public offering, and BofA Securities, Inc., Goldman Sachs & Co. LLC, UBS Securities LLC, Itau BBA USA Securities, Inc., Morgan Stanley & Co. LLC, Banco BTG Pactual S.A.– Cayman Branch and XP Securities, LLC are collectively acting as Bookrunners in the offering.

The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from BofA Securities, Inc. NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attention: Prospectus Department or by emailing dg.prospectus_requests@baml.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com; UBS Securities LLC, Attn: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, by telephone at (888) 827-7275 or by email at ol-prospectus-request@ubs.com; Itau BBA USA Securities, Inc., 540 Madison Avenue 24th Floor, New York, New York 10022, Attention: Equity Sales Desk, telephone: 1-212-710-6756 or by emailing roadshowdesk@itaubba.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Banco BTG Pactual S.A.–Cayman Branch at Attention: Prospectus Department, 601 Lexington Avenue, 57th Floor, New York, New York 10022, email: OL-BTGPactual-ProspectusDepartment@btgpactual.com; or XP Securities, LLC, Tower 46 | 55 West 46th Street, 30th Floor, New York, New York 10036.

A registration statement relating to these securities has been filed with, and became or was declared effective by the U.S. Securities and Exchange Commission (“SEC”). Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov.

This announcement does not, and is not intended to, constitute an offer to sell or a solicitation of an offer to purchase any securities in the United States or elsewhere, and it does not, and is not intended to, constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

About Afya
Afya is a leading medical education group in Brazil based on number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students to be lifelong medical learners from the moment they join us as medical students through their medical residency preparation, graduation program, and continuing medical education activities.

Contact:
Investor Relations: ir@afya.com.br

SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES

— Collaboration advances Silence’s proprietary platform in the growing field of RNAi technology

 — Agreement provides Mallinckrodt with an exclusive worldwide license for one preclinical asset that targets a specific protein in the complement pathway, C3 (SLN500), and an option for up to two additional assets with different complement protein targets

— Silence to receive a $20 million upfront payment, potential near- and long-term development and commercial milestones, and royalties on net sales

— Silence will host a webinar today at 1:00 p.m. BST¹ to discuss the announcement

LONDON and STAINES-UPON-THAMES, United Kingdom, July 18, 2019 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Silence Therapeutics plc (LON: SLN), a leader in the discovery, development and delivery of novel RNA² interference (RNAi) therapeutics for the treatment of serious diseases, today announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or ‘silence’ the complement cascade, a group of proteins that are involved in the immune system and that play a role in the development of inflammation. These proteins are known to contribute to the pathogenesis of many diseases, including autoimmune diseases.

Under the terms of the agreement, Mallinckrodt will obtain an exclusive worldwide license to Silence’s C3³ complement asset, SLN500, with options to license up to two additional complement-targeted assets in Silence’s preclinical complement-directed RNAi development program. Silence will be responsible for preclinical activities, and for executing the development program of each asset until the end of Phase 1, after which Mallinckrodt will assume clinical development and responsibility for global commercialization.

Mallinckrodt has agreed to provide Silence with an upfront payment of $20 million. Silence is also eligible to receive up to $10 million in research milestones for SLN500 and for each optioned asset, in addition to funding for Phase 1 clinical development including GMP⁴ manufacturing. Silence will fund all other preclinical activities. The collaboration provides for potential added clinical and regulatory milestone payments of up to $100 million for SLN500, as well as commercial milestone payments of up to $563 million for SLN500. Should Mallinckrodt opt to license one or two additional assets, Silence could receive up to $703 million in similar clinical, regulatory, and commercial milestone payments per asset. Silence would also receive tiered, low double-digit to high-teen royalties on net sales for SLN500 and each optioned asset.

“We are very excited by the significant potential offered by Silence’s RNAi technology to meet the needs of underserved patients in a number of serious and critical conditions, and we look forward to collaborating with them to advance development of complement-targeted assets as new therapeutic options,” said Steven Romano, M.D., Chief Scientific Officer and Executive Vice President of Mallinckrodt.

“This license provides Mallinckrodt with an expansion of early development opportunities and the value of applying RNA technology therapeutically to target a range of rare diseases as well as conditions of immune dysregulation,” adds Ulrich H. von Andrian, M.D., Edward Mallinckrodt Jr. Professor of Immunopathology, Microbiology and Immunobiology, Harvard Medical School and Member of the Mallinckrodt Pharmaceuticals Scientific Advisory Council.

“This collaboration combines Silence Therapeutics’ knowledge and world-class research and development in the field of RNAi with Mallinckrodt’s expertise and resources as a global biopharmaceutical company with years of experience solving complex challenges,” said Dr. David Horn Solomon, President and Chief Executive Officer of Silence Therapeutics. “The increasing number of clinical conditions and pathologies that involve the complement system has generated significant interest in the development of therapeutic options to inhibit complement activation, which holds great promise in treating a range of diseases. We look forward to working closely with Mallinckrodt to extend our capabilities with RNAi therapies that have the potential to transform patients’ lives.”

The companies will work together to develop and commercialize this RNAi therapeutic target, with the possibility of additional assets, and will form a Joint Steering Committee to guide the asset’s development program. Silence’s proprietary technology is a highly specific and modular platform designed to inhibit or ‘silence’ the expression of disease-causing genes. The technology is appropriate to target any number of genes; however, the collaboration focuses on the complement cascade, which is implicated in a number of autoimmune diseases.

Silence Call with Investors
Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, will host a conference call accompanied by a live presentation for analysts and investors today at 13.00pm BST (8.00am EDT). Link to the live webcast: https://edge.media-server.com/mmc/p/d4noa4jd. Dial-in details are: Participant UK dial-in: +44 (0) 2071 928000; Participant; US Dial-in: +1 631 510 7495 Conference ID: 1576453.  A presentation to accompany the call will be made available to download from https://www.silence-therapeutics.com/investors/results-reports-presentations.

ABOUT SILENCE
Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. Silence Therapeutics remains focused and is determined to be responsive to creating shareholder value as well as the appropriate growth and development of its business. Silence Therapeutics continues to assess a number of options in addition to its organic plan which it believes would be additive to the Company’s future growth prospects and shareholder value, which may include equity fundraisings as well as other strategic licensing and collaboration opportunities. For more information, please visit https://www.silence-therapeutics.com/.

ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company’s Specialty Brands reportable segment’s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Cautionary Statements Related to Forward-Looking Statements
Mallinckrodt
This release includes forward-looking statements concerning Mallinckrodt’s collaboration with Silence, including expectations regarding future research and development plans, potential milestone payments and commercial arrangements and the potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: uncertainties inherent in research and development, including clinical trial results; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; issues with product quality, manufacturing or supply, or patient safety issues; and other risks identified and described in more detail in the “Risk Factors” section of Mallinckrodt’s most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

Silence
The information contained within this announcement is deemed by the Silence Therapeutics plc to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

CONTACTS

MALLINCKRODT
Investor Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com

Media
Daniel Yunger
Kekst CNC
212-521-4879
mallinckrodt@kekstcnc.com

SILENCE THERAPEUTICS
Dr. David Horn Solomon, Chief Executive Officer
Mr. Iain Ross, Non-Executive Chairman
+44 (0) 20 3457 6900

Peel Hunt/LLP (Nominated Adviser and Broker)
James Steel/Oliver Jackson
+44 (0) 20 7418 8900

European IR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gary
silencetherapeutics@consilium-comms.com
+44 (0) 20 3709 5700

US IR
Westwicke Partners
Peter Vozzo
Peter.vozzo@westwicke.com
442-213-0505

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2019 Mallinckrodt. 7/19

¹ British Summer Time

² Ribonucleic acid

³ The C3 protein is part of the complement system. There are nine major complement proteins, labeled C1 through C9. https://medlineplus.gov/ency/article/003539.htm Accessed June 27, 2019.

⁴ Good manufacturing practices

DENVER, July 17, 2019 (GLOBE NEWSWIRE) — Sundance Energy Australia Limited (ASX: SEA) (NASDAQ: SNDE) (“Sundance” or the “Company”), a U.S. onshore oil and gas exploration and production company focused in the Eagle Ford in South Texas, today announced that it had entered into a definitive agreement to sell its assets in Dimmit County, TX (the “Assets”) for a purchase price of US$29.5 million, subject to customary adjustments at closing.

The Assets comprise 19 gross producing wells on ~6,100 net acres and contributed 1,051 boepd in average daily sales volumes for the first quarter of 2019. The sale is anticipated to close prior to the end of September 2019.

In anticipation of this transaction sale, the Company’s recently announced ~40% increase to its borrowing base facility did not include any reserves associated with the Assets in the calculation of the borrowing base. As such, the borrowing base will remain unchanged upon the close of the sale. Additionally, the Company’s previously released public guidance excluded any contribution from the Assets beginning in May 2019.

Sundance’s Chief Executive Officer and Managing Director, Eric McCrady, commented, “The impending successful sale of our Dimmit assets at an attractive price will only serve to add to the Company’s already strong liquidity position. The cash consideration, in addition to the existing availability under our borrowing base, provides an ample liquidity cushion while we work towards reaching free cash flow generation in the second half of the year.”

About Sundance Energy Australia Limited

Sundance Energy Australia Limited (“Sundance” or the “Company”) is an Australian-based, independent energy exploration company, with a wholly owned US subsidiary, Sundance Energy Inc., located in Denver, Colorado, USA. The Company is focused on the acquisition and development of large, repeatable oil and natural gas resource plays in North America. Current activities are focused in the Eagle Ford.  A comprehensive overview of the Company can be found on Sundance’s website at www.sundanceenergy.net

Summary Information

The following disclaimer applies to this document and any information contained in it. The information in this release is of general background and does not purport to be complete. It should be read in conjunction with Sundance’s periodic and continuous disclosure announcements lodged with ASX Limited that are available at www.asx.com.au and Sundance’s filings with the Securities and Exchange Commission available at www.sec.gov.  

Forward Looking Statements

This release may contain forward-looking statements. These statements relate to the Company’s expectations, beliefs, intentions or strategies regarding the future. These statements can be identified by the use of words like “anticipate”, “believe”, “intend”, “estimate”, “expect”, “may”, “plan”, “project”, “will”, “should”, “seek” and similar words or expressions containing same.

These forward-looking statements reflect the Company’s views and assumptions with respect to future events as of the date of this release and are subject to a variety of unpredictable risks, uncertainties, and other unknowns. Actual and future results and trends could differ materially from those set forth in such statements due to various factors, many of which are beyond our ability to control or predict. These include, but are not limited to, risks or uncertainties associated with the discovery and development of oil and natural gas reserves, cash flows and liquidity, business and financial strategy, budget, projections and operating results, oil and natural gas prices, amount, nature and timing of capital expenditures, including future development costs, availability and terms of capital and general economic and business conditions. Given these uncertainties, no one should place undue reliance on any forward looking statements attributable to Sundance, or any of its affiliates or persons acting on its behalf.  Although every effort has been made to ensure this release sets forth a fair and accurate view, we do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact: